Valbonne, France, February 9, 2016 – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T-cells to treat severe chronic inflammatory and autoimmune diseases, announces today that Stephane Boissel, CEO, TxCell and other senior management will either attend, present to, and meet investors at a number of leading forthcoming investor conferences.
The conferences give TxCell the opportunity to continue to update investors about the potential and opportunities in the cellular therapy market as well as achievements by TxCell following the reorganization and refocusing of the Company conducted throughout 2015.
TxCell’s recent strategic decisions enable TxCell to open a totally new chapter and so present its ambitious new targets, including this of bringing at least three new products to clinical development within five years. These decisions include firstly, to outsource manufacturing activities to concentrate its effort and resources on research and development, including process development. Secondly TxCell decided to reacquire the full rights to its lead product Ovasave(R) and lastly, to accelerate its efforts on its second product platform of CAR-Treg cells.
The next investor conferences that TxCell will participate in include:
• European Midcap Event, 9th edition, Frankfurt, Germany - February 17, 2016
• 2016 Credit Suisse London Healthcare Conference, London, UK - March 1-2, 2016
• BioCapital Europe, Amsterdam, The Netherlands – March 9, 2016
• 4th Alliance for Regenerative Medicine Annual Cell and Gene Investor Day, New York, USA – March 22, 2016
About TxCell: www.txcell.com
TxCell is a publicly listed biopharmaceutical company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need. TxCell is the only clinical stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated. Ovasave(R), TxCell’s lead product candidate, is currently in a phase IIb clinical trial in refractory Crohn’s disease patients. Col-Treg, its second product candidate, for the treatment of autoimmune uveitis, should enter clinical trials in 2016. Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 49 employees.
